They are looking for Editor in Chief position. The appointment will be from January 2024 for an initial three-year term, with scope to extend subject to mutual interest.
This is the position announcement: https://academic.oup.com/jhc/pages/editor-in-chief-application
They are looking for Editor in Chief. The Editor-in-Chief is expected to provide innovative leadership in the evolving area of scientific communication while fulfilling best publishing practices that advance the journal. The Editor-in-Chief is expected to serve in the position for an initial five-year term, with potential renewal for an additional term. This is the announcement: https://nutrition.org/publications/jn-editor-in-chief/
They are looking for an Editor-in-Chief for the journal with relevant backgrounds to the field and the vision and desire to continue the journal’s growth, maintain its reputation, and work productively with Sprinter-Nature and BMES staff. The role will serve an initial three-year term, with the potential for a second three-year term. This is their announcement: https://www.bmes.org/news/open-editor-in-chief-positions
They are looking for an Editor-in-Chief for the journal with relevant backgrounds to the field and the vision and desire to continue the journal’s growth, maintain its reputation, and work productively with Sprinter-Nature and BMES staff. The role will serve an initial three-year term, with the potential for a second three-year term. This is their announcement: https://www.bmes.org/news/open-editor-in-chief-positions
Seem an interesting paper. How has the treatment of AL amyloidosis evolved over the past three decades, particularly in terms of patient eligibility, stem cell collection, and the integration of novel therapies, and what are the long-term outcomes and current challenges in managing this condition?
Very interesting! This paper assesses autologous peripheral blood stem cell transplantation in treating hepatitis B-induced liver cirrhosis. Involving 51 patients, it compares a treatment group receiving stem cell transplantation and medical treatment with a control group receiving only medical treatment. Results over 48 weeks show significant improvements in liver function and symptom relief in the treatment group, suggesting the potential effectiveness of this approach for liver cirrhosis caused by hepatitis B.
This study contrasts immune recovery in umbilical cord blood (UCB) and HLA-matched unrelated donor (MUD) stem cell transplant recipients. It finds a notable delay in T cell recovery up to 6 months post-transplant in UCB patients, while their B and NK cell recovery is faster. Early high BAFF levels in UCB patients contribute to quicker B cell reconstitution, potentially reducing chronic graft-versus-host disease incidence. However, UCB recipients face increased infectious risks due to a significant T cell deficiency in the first 6 months.
Non-academic career paths leverage the interdisciplinary training of biological physicists and their ability to tackle complex problems, making them well-suited for a range of industries beyond academia.
Lowering LDL cholesterol is essential for reducing cardiovascular disease risks, typically addressed with lifestyle changes and medications like statins. For high-risk patients who don't meet LDL targets with statins and ezetimibe, PCSK9 inhibitors have shown promise. These inhibitors are particularly effective for patients with familial hypercholesterolemia. While statins can increase PCSK9 levels and potentially diminish their effectiveness, the role of PCSK9 as a cardiovascular risk predictor remains unclear. Emerging treatments aim to inhibit PCSK9 more effectively. Further research is needed to understand the clinical significance of PCSK9 levels in cardiovascular risk assessment and treatment resistance.
This study explores the connection between lipid-lowering drugs and psoriasis risk, focusing on genetically proxied inhibition of certain enzymes (HMGCR, NPC1L1, and PCSK9) using data from large genome-wide association studies. It found that inhibition of PCSK9, associated with lower LDL levels, was linked to a reduced risk of psoriasis, a finding supported by two large datasets. The study did not find a robust association for HMGCR or NPC1L1 inhibition. These results, derived from mendelian randomization, suggest PCSK9 plays a role in psoriasis pathogenesis and that its inhibition could potentially lower psoriasis risk.
Great paper, I have copied and pasted the 10 rules here
Rule 1: Clarify your audience
Rule 2: Make lessons modular
Rule 3: Teach best practices for lesson development
Rule 4: Encourage and empower contributors
Rule 5: Build community around lessons
Rule 6: Publish periodically and recognize contributions
Rule 7: Evaluate lessons at several scales
Rule 8: Reduce, reuse, recycle
Rule 9: Link to other resources
Rule 10: You can’t please everyone
Great review paper for how to structure a paper, so I have copied and pasted the top 4 rules here:
Rule 1: Focus your paper on a central contribution, which you communicate in the title
Rule 2: Write for flesh-and-blood human beings who do not know your work
Rule 3: Stick to the context-content-conclusion (C-C-C) scheme
Rule 4: Optimize your logical flow by avoiding zig-zag and using parallelism
Very interesting! This paper examines alternative forms of interdisciplinary working in Irish primary care beyond the National Primary Care Strategy's framework, revealing that local, innovative, and preventive patient-centered approaches driven by diverse professional groups show positive impacts but face challenges due to economic constraints and lack of recognition by senior management.
This study developed a blood test for early detection of breast cancer using mRNA-based tests, demonstrating superior sensitivity, specificity, and accuracy compared to conventional methods across various cancer stages, offering a promising tool for precision oncology.
期刊